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Simple Summary: Antiestrogen hormonal therapy is a relatively low side effect, orally administered
cancer treatment option, yet response rates have been limited in epithelial ovarian cancer despite
estrogen receptor expression in many tumors. This suggests that other pathways impact estrogen
response. Cytokine signaling from the tumor microenvironment promotes ovarian cancer growth,
and crosstalk between cytokine signaling and estrogen signaling has been reported in other tumor
types. We therefore aimed to investigate whether cytokine signaling impacts estrogen signaling in
high-grade serous ovarian cancer. We demonstrated crosstalk between these two pathways in patientderived samples, in vitro and in animal studies. We found that inhibiting interleukin-6/leukemia
inhibitory factor (IL6/LIF) cytokine signaling activates estrogen signaling and blocking both pathways
was synergistic in inhibiting tumor cell growth. These results suggest a potential role for combination
therapy for epithelial ovarian cancer patients.
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Abstract: Antiestrogen therapy (AET) is an alternative to cytotoxic chemotherapy for recurrent
ovarian cancer, yet the often short duration of response suggests mechanisms of resistance. We
previously demonstrated that tumor microenvironment interleukin-6/leukemia inhibitory factor
(IL6/LIF) cytokines induce tumor cell JAK-STAT signaling to promote cancer growth. Crosstalk
between estrogen signaling and cytokine signaling has been reported. Therefore, we sought to
characterize the impact of IL6/LIF signaling on estrogen signaling in epithelial ovarian cancer
and investigate the efficacy of combination therapy. We first assessed patient tumors for cytokine
expression and compared it with response to AET to determine clinical relevance. In vitro, we
determined the effect of IL6/LIF on estrogen receptor expression and signaling. Cell viability
assays were used to determine the efficacy and potential synergy of cytokine blockade and AET. We
then extended studies to animal models, incorporating patient-derived stromal cells. Our results
demonstrated shorter progression-free interval on AET in patients with stromal IL6/LIF expression.
In vitro, IL6/LIF increased tumor cell estrogen receptor expression and signaling, and combination
cytokine blockade and AET resulted in synergistic inhibition of tumor cell growth. The anticancer effect
was verified in a mouse model. In conclusion, due to crosstalk between IL6/LIF cytokine signaling and
estrogen signaling, dual blockade is a potential new treatment approach for ovarian cancer.
Keywords: mesenchymal stem cells; ovarian cancer; leukemia inhibitory factor (LIF); interleukin-6 (IL6);
STAT3; JAK2 inhibition; estrogen receptor; antiestrogen therapy (AET)
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1. Introduction
Ovarian cancer is the fifth highest cause of cancer deaths among women in the United
States, with a 5-year survival rate of less than 50%. Cancers of ovarian, fallopian tube
and primary peritoneal origins are frequently collectively termed “ovarian cancer”, with
high-grade serous carcinoma (HGSC) being the most common and most lethal epithelial
subtype. Most HGSC patients initially respond to cytotoxic chemotherapy, but later develop
recurrent disease that is resistant to standard treatments. Platinum-resistant ovarian cancer
is generally treated with single agent cytotoxic chemotherapy with palliative intent [1],
with objective response rates ranging from 10–30% and a median progression-free interval
(PFI) of 3–5 months [2,3]. Given this limited efficacy and the potential for significant side
effects with cytotoxic chemotherapy agents, it is imperative to develop new treatment
approaches that improve efficacy and/or prioritize quality of life factors.
One potential alternative to cytotoxic chemotherapy for the treatment of HGSC is a
hormonal approach utilizing antiestrogen therapy (AET). We previously reported a cohort
of heavily pre-treated ovarian cancer patients with a median PFI of 4.0 months on AET,
including responses in some patients with ER-negative tumors [4]. These data are in
alignment with the finding that approximately 80% of epithelial ovarian cancers express
estrogen receptor-alpha (ERα) [5], yet a 20% response rate to AET is noted in clinical
studies [6]. Together, these findings suggest modifiers of response that can potentially be
targeted to improve hormonal therapy response rates in HGSC.
Ovarian cancer-associated mesenchymal stem cells (CA-MSC) in the tumor microenvironment promote tumorigenesis through the secretion of factors including interleukin-6
(IL6) and the related cytokine leukemia inhibitory factor (LIF) [7,8]. IL6 cytokine expression has been shown to be inversely correlated with AET response in ovarian cancer cell
lines [9,10]. Stromal IL6 signaling has been shown to alter hormone metabolism in ERnegative breast cancers [11] and crosstalk between estrogen and IL6 signaling in the tumor
microenvironment has been reported in prostate cancer cell lines [12]. LIF signaling has
also been implicated in tumorigenesis, and we previously demonstrated that LIF functions
in parallel with IL6, thus requiring dual cytokine blockade for optimal antitumor effects [8].
Furthermore, IL6 has been shown to regulate and enrich ovarian cancer stemness following
platinum-based therapy [13].
Based on these clinical and preclinical data, we hypothesized that there is crosstalk
between cytokine signaling and estrogen signaling pathways in HGSC; thus, inhibition of
cytokine signaling including that from the tumor microenvironment may sensitize ovarian
cancers to AET. Herein, we report on the ability of IL6/LIF cytokine signaling to increase
ER signaling and the use of dual cytokine and estrogen blockade to decrease HGSC cell
growth in vitro synergistically as well as in vivo in animal models. These findings suggest
a novel combination therapy for the treatment of ovarian cancer.
2. Materials and Methods
2.1. Cell Lines
Ovarian cancer cell lines OVSAHO, SKOV3, COV362, CaOV3 and breast cancer
cell lines T47D and MCF7 were obtained from the American Type Culture Collection
(ATCC). OVCAR3 and OVCAR4 were obtained from the National Cancer Institute. SNU119
was purchased from AcceGen Biotechnology (Fairfield, NJ, USA). Cell line identity was
validated by STR profile report using the ATCC Cell Line Authentication service. Cell
lines were maintained in standard culture conditions. Mycoplasma testing was performed
(PlasmoTest Kit, Invivogen, San Diego, CA, USA) and confirmed to be negative at least
every two months to maintain healthy cell cultures.
2.2. Patient-Derived Samples
Primary, patient-derived specimens from women undergoing surgery at our institution
were obtained through institutional review board-approved protocols (HUM00125624,
HUM00148299). Cancer-associated mesenchymal stem cells (CA-MSC) were isolated and
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maintained as previously described [7,8]. For conditioned media experiments, cells were
cultured in serum-free media for 24 h prior to collection of media. As controls, noncancer human adipose-derived mesenchymal stem cells were purchased from ATCC (Cat.
No. PCS-500-011) or Invitrogen (Cat. No. R7788115) (Manassas, VA, USA).
2.3. Immunohistochemical Analysis of Primary Patient Tumors
Under an institutional review board-approved protocol (HUM00072411), patients
with a history of ovarian cancer and AET were identified. Clinical outcomes were obtained through data extraction from the electronic medical record and correlated with ERα
expression as previously reported [4]. For that study, ERα immunohistochemistry was
performed with the antibody clone 1D5 (BIOCARE, Pacheco, CA, USA, Cat. No. ACA054A)
and an Allred score of 0–8 applied, with a score ≥ 3 indicating ERα positivity. For the
present study, formalin-fixed, paraffin-embedded tumor specimens were assessed by immunohistochemistry for IL6 expression (primary antibody from Abcam, Cambridge, UK,
Cat. No. ab9324) and LIF expression (primary antibody from Abcam, Cat. No. ab135629).
Staining was scored by a board-certified pathologist, and positivity was determined based
on the presence of granular or diffuse staining within the cytoplasm and nucleus of the
cells of interest. IHC for both IL6 and LIF was then analyzed via a combination of the aggregate percentage of stained cells and the intensity of cell staining (0 = negative; 1+ = mild;
2+ = moderate; 3+ = strong). Presence or absence of stromal staining was utilized for
survival analyses.
2.4. Cell Viability Assays
Media was changed to 2% charcoal-stripped fetal bovine serum (FBS) at 24 h and then
cells were plated in 96 well plates. After 24 h, fresh media with 2% charcoal-stripped FBS
was placed without or with the following drugs: tamoxifen (Sigma, St. Louis, MO, USA,
T5648), letrozole (Sigma, L6545) or ruxolitinib (Selleckchem, Radnor, PA, USA, S1378). Cell
viability was determined with the MTT Cell Viability Assay Kit (Biotium, Fremont, CA,
USA, Cat. No.30006).
2.5. Reporter Assays
The ERE Cignal Reporter Assay Kit (QIAGEN, Hilden, Germany, Cat. No. CCS-005L)
was used per the manufacturer’s instructions, with plasmid complexes transfected into the
cells with Lipofectamine 2000 in OptiMEM media 10% charcoal-stripped FBS. After 6 h,
media was changed to standard media with 2% charcoal-stripped FBS without antibiotics
and without or with the indicated treatment of estradiol, IL6, LIF, IL6 + LIF, or mock
treatment. After 24 h of treatment, luciferase signal intensities were quantified per the
manufacturer’s protocol (Dual-Glo Luciferase Assay System, Promega Cat. No. E2920) and
reporter assay activation calculated compared to controls.
2.6. Immunoblotting
To assess basal ER expression levels, cells were cultured in standard conditions and
protein lysates harvested in RIPA lysis buffer (Sigma, R0278). To determine the impact of
cytokine signaling on ER expression levels, tumor cells were treated with either CA-MSC
condition media, or serum-free media containing 50 ng/mL recombinant IL6 (4-8069-80,
eBioscience) and/or 50 ng/mL recombinant LIF treatment (14-8460-80, eBioscience) for
24 h. RIPA lysates were prepared and subjected to immunoblotting with antibodies to ERα
(Abcam, Cat. No. ab116716), followed by secondary antibody (Cell Signaling, Danvers, MA,
USA, Cat. No. 7074S). The membrane was developed with Pierce ECL solution (Thermo
Scientific, Waltham, MA, USA, 23106). GAPDH immunoblotting was utilized as a loading
control.
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2.7. Colony Formation Assay
Ovarian cancer cells were seeded in 24-well plates (200 cells/well, in triplicates) and
cells were treated with vehicle control, ruxolitinib, letrozole and ruxolitinib/letrozole in
combination at the indicated concentrations for two weeks to allow for colony formation.
Medium was changed every third day. Visible colonies were fixed with 4% paraformaldehyde and stained with 0.005% crystal violet at RT for 5 min following distilled water
washing. The number of colonies per well was counted.
2.8. Animal Studies
All studies were performed under institutional animal care and use committee (IACUC)approved protocols and regulations. Female NSG mice were obtained from Jackson Laboratories (strain 005557). An initial pilot experiment was performed to characterize tumor
growth rates and dosing schedules, followed by a second experiment to quantify treatment
effects. At approximately eight weeks of age, the mice underwent bilateral ovariectomy.
After two weeks of healing, mice were injected subcutaneously with 0.5 × 106 OVCAR3
human epithelial ovarian cancer cells and 0.5 × 106 patient-derived CA-MSC suspended
in Matrigel. Tumors reached approximately 200 mm3 after ten days; animals were then
randomized to treatment groups by even distribution of starting weights and tumor size
(n = 5 per group, sample size selected empirically). Cohorts were treated with (1) control chow (Incyte Corp., Palo Alto, CA, USA), (2) ruxolitinib chow (2 g/kg chow, Incyte
Corp.), (3) control chow plus letrozole or (4) ruxolitinib chow plus letrozole. Letrozole
was dissolved in 2% DMSO w/98% PBS (L6545 Sigma) and 20 ug daily administered
intraperitoneally. Animals were sacrificed at either > 10% weight loss or significant illness,
as discussed with the animal care facility.
2.9. Statistical Analysis
All experiments were performed in duplicate or triplicate, and all data are expressed
as the mean ± standard deviation. Statistical analysis was performed using GraphPad
Prism version 8.0 for Windows (GraphPad Software, San Diego, CA, USA). For single
comparisons, an unpaired, two-tailed t test was used. For multiple comparisons, one-way
analysis of variance (ANOVA) with Tukey’s or Bonferroni post hoc test was performed. For
survival curve comparisons, statistical analysis was performed with the log-rank MantelCox method. Results were considered statistically significant with a p value of ≤0.05. For
all figures, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
3. Results
3.1. Stromal IL6/LIF Cytokine Expression Is Correlated with a Shorter Progression-Free Interval on
Antiestrogen Therapy
To define a clinical relevance for the relationship between IL6/LIF expression and
response to AET, we examined the expression of ERα, IL6 and LIF in tumor specimens
derived from a cohort of patients with ovarian, Fallopian tube or primary peritoneal cancer
treated with AET (Figure 1A) [4] and assessed the correlations between expression patterns
and PFI. The majority of the patients in the cohort had advanced stage, high-grade serous
carcinoma. Approximately 73% received tamoxifen as their AET, 9% received the aromatase
inhibitor letrozole and 18% received the aromatase inhibitor anastrozole.

Cancers 2022, 14, 4675

than patients with IL6/LIF-negative tumors (n = 31, mean PFI = 6.4 months), p = 0.07
ure 1C). We then examined the subset of patients with ERα-positive tumors (n
Amongst this subset of patients, those with tumors that expressed IL6/LIF in the s
(n = 9) had a statistically significant shorter mean PFI (4.1 months) compared to pa
with tumors that lacked IL6/LIF expression in the stroma (n = 19, mean PFI = 8.6 mo
5 ofof
11 IL6/LIF
p = 0.019 (Figure 1D). Collectively, these data suggest that expression
tumor microenvironment is negatively correlated with response to AET.

Figure 1. The role
of ERα
expression
in response
to AET.
For a cohort
of patients
treated
Figure
1. and
The IL6/LIF
role of ERα
and IL6/LIF
expression
in response
to AET.
For a cohort
of patients
with AET, tumors
were
stained
forwere
ERα stained
expression
by IHC
and staining
scored
thescored
Allredusing the
with
AET,
tumors
for ERα
expression
by IHC
and using
staining
method. (A) of
Characteristics
of patients
treated
with AET. (B) histologic
Representative
histologic fin
method. (A) Characteristics
patients treated
with AET.
(B) Representative
findings,
including
positive
and
negative
staining.
(C)
Progression-free
interval
on
AET
in IL6/LIF
including positive and negative staining. (C) Progression-free interval on AET in IL6/LIF stroma
positive
versus
negative
tumors
for
entire
cohort
and
(D)
Progression-free
interval
on A
positive versus negative tumors for entire cohort and (D) Progression-free interval on AET in IL6/LIF
IL6/LIF
stroma
positive
versus
negative
tumors
for
patients
with
ERα
positive
tumors.
Sta
stroma positive versus negative tumors for patients with ERα positive tumors. Statistical analysis
analysis performed with the log-rank Mantel-Cox method; p values shown.
performed with the log-rank Mantel-Cox method; p values shown.

3.2.
IL6 and LIF
Increase
Tumor
Expression
Tumor ERα
expression
wasSignaling
previously
scored
usingCell
the ERα
validated
Allred method [4,14].
To test
hypothesis
that cytokine
from the
ovarian
cancer tumor
Immunohistochemistry
wasour
performed
to assess
IL6 and signaling
LIF expression
in both
the tumor
cells and surrounding
stroma.
Stained
tumor
slides were
scored we
by assessed
a board-certified
environment
impacts
tumor
cell estrogen
pathways,
the impact of CA
pathologist; representative
positive
staining
are shown (Figure
1B). Given
conditioned media
onand
ERαnegative
expression
by immunoblotting.
High-grade
serous carc
the redundancy
in
IL6/LIF
signaling
through
the
GP130
coreceptor
and
downstream
OVCAR3 cells were grown in one of three mesenchymal media conditions: (1) c
JAK/STAT signaling
cascade,
were
scored
positivefollowing
if they expressed
either
MSC media,
(2) tumors
media that
had
been as
collected
culture with
CA-MSC t
cytokine in theconditioned
tumor microenvironment.
media (CM), or (3) CA-MSC CM treated with the JAK inhibitor ruxo
In the entire
cohort2A).
of patients
(n = 44) treated
with AET,
we found
thatCA-MSC
patients with
(Figure
ERα expression
was noted
to increase
with
conditioned
IL6/LIF stroma-positive tumors (n = 13) trended toward a shorter mean PFI (4.3 months)
than patients with IL6/LIF-negative tumors (n = 31, mean PFI = 6.4 months), p = 0.072
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3.2. IL6 and LIF Signaling Increase Tumor Cell ERα Expression
To test our hypothesis that cytokine signaling from the ovarian cancer tumor microenvironment impacts tumor cell estrogen pathways, we assessed the impact of CA-MSC
conditioned media on ERα expression by immunoblotting. High-grade serous carcinoma
OVCAR3 cells were grown in one of three mesenchymal media conditions: (1) control
MSC media, (2) media that had been collected following culture with CA-MSC termed
conditioned media (CM), or (3) CA-MSC CM treated with the JAK inhibitor ruxolitinib
(Figure 2A). ERα expression was noted to increase with CA-MSC conditioned media when
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practice at this therapy
time andwas
its oral
bioavailability
translational
studies. ERα-high ov
redundancy of the pathways in impacting HGSC cell signaling [8]. ERE reporter activation
following E2 treatment mirrored ERα expression, with activation inOVCAR3, OVSAHO
and OVCAR8 cell lines (Figure 3C). The ERα-low high-grade serous lines COV362, OVCAR4 and SNU119 did not demonstrate ERE reporter activation following E2 therapy
(Figure 3D). In the ERα-high HGSC cell lines (Figure 3C), there was a statistically significant increase in luciferase reporter activation when treated with IL6 + LIF (p < 0.001
for OVCAR3, p = 0.046 for OVSAHO, and p < 0.007 for OVCAR8). In comparison, the
ERα-low cell lines COV362, OVCAR4 and SNU119 did not show an increase in luciferase
ERE reporter activation following IL6 + LIF therapy (Figure 3D). These findings support
IL6/LIF activation of ER signaling in ERα-positive high-grade serous tumors.

3.4. Letrozole and Ruxolitinib Demonstrate Synergy in Ovarian Cancer Cell Lines
After establishing the ability of cytokines IL6/LIF to activate ERα expression and
estrogen signaling, we sought to examine the effect of combination therapy blocking both
pathways on cell viability. We investigated the impact of cytokine signaling inhibition using
the JAK2 inhibitor in combination with the aromatase inhibitor letrozole. Letrozole was
selected as the antiestrogen for further studies based on its preferred use in clinical practice
at this time and its oral bioavailability for translational studies. ERα-high ovarian cancer
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cancer cell lines OVCAR3 and OVCAR8 were treated with a range of doses of ruxolitinib
and letrozole at a 1:2 ratio and cell viability was quantified. Combination index
was
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11 calculated using the Chou-Talalay method [15], with a combination index of <1 indicating
synergy. In both OVCAR3 and OVCAR8, the combination of ruxolitinib and letrozole resulted in synergistic cell killing (Figure 4A).
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treatment
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letrozole at a 1:2 ratio and cell viability was quantified. Combination index was calculated
concentrations, again employing the 1:2 ratio. The combination of ruxolitinib and letrozole
using the Chou-Talalay method [15], with a combination index of <1 indicating synergy.
showed a visible inhibition in colony number compared to control and single drug wells
In both OVCAR3(Figure
and OVCAR8,
the combination
of ruxolitinib
letrozole
resulted assays,
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4B). Combination
index was determined
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synergistic cell killing
(Figure
4A).
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representation demonstrating synergy in the colony formation assay.
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graphical representation
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results,
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assessing thewith
impact
of combination
alone, letrozole alone,
and
combination
treatment
of
ruxolitinib
and
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at
therapy, consisting of cytokine blockade and AET, on tumor growth in adifferent
mouse model
concentrations, again
employing
1:2 ratio.
combination
of ruxolitinib
and
letrozole
system.
Followingthe
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experiment
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methodology
and
time course,
mice in
were
ovariectomized
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with
OVCAR3
plusdrug
patient-derived
showed a visible female
inhibition
colony
number compared
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andcells
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wells
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weredetermined
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fouron
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(n = 5 animals
each, with
bilateral
(Figure 4B). Combination
index was
based
the colony
formation
assays,
tumors for 10 evaluable tumors per cohort) and treated as follows: (1) control chow, (2)
again demonstrating synergy (Figure 4B).
ruxolitinib chow, (3) control chow plus letrozole or (4) ruxolitinib chow plus letrozole.
Tumor growth curves and final tumor weights were assessed; both were consistent with
3.5. Combination Therapy with AET and Cytokine Blockade Improves Treatment Response In Vivo
decreased tumor burden in both single agent groups and combination therapy groups
We next sought
to extend
our findings
in vivo
assessing
impact
combination
compared
to controls
(Figure 5A,B).
Atby
time
of animalthe
sacrifice,
allof
treatments
showed a
statistically
significant
difference
in
final
tumor
weight
when
compared
the control
therapy, consisting of cytokine blockade and AET, on tumor growth in a mousetomodel
group.
Combination
therapy withtoletrozole
plus
ruxolitinib didand
nottime
showcourse,
statistically
system. Following
an initial
pilot experiment
establish
methodology

female mice were ovariectomized and injected with OVCAR3 cells plus patient-derived
CA-MSC. Animals were then divided into four cohorts (n = 5 animals each, with bilateral
tumors for 10 evaluable tumors per cohort) and treated as follows: (1) control chow,
(2) ruxolitinib chow, (3) control chow plus letrozole or (4) ruxolitinib chow plus letrozole.
Tumor growth curves and final tumor weights were assessed; both were consistent with
decreased tumor burden in both single agent groups and combination therapy groups
compared to controls (Figure 5A,B). At time of animal sacrifice, all treatments showed a
statistically significant difference in final tumor weight when compared to the control group.
Combination therapy with letrozole plus ruxolitinib did not show statistically significant
decreases in tumor size as compared to the single agent group. However, the letrozole plus
letrozole group had the lowest average tumor weight (1732 mg), which was statistically
significant compared to the control group (2574 mg, p < 0.001) (Figure 5B).
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animals each) of control chow, ruxolitinib chow, letrozole intraperitoneally, or ruxolitinib chow plus
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4. Discussion
4. Discussion
Recurrent ovarian cancer is a clinical challenge requiring new treatment approaches
Recurrent ovarian cancer is a clinical challenge requiring new treatment approaches
that consider the optimization of patient quality of life. Despite most epithelial ovarian
that consider the optimization of patient quality of life. Despite most epithelial ovarian
cancers expressing ER, clinical response rates to AET have been disappointing. Based on
cancers expressing ER, clinical response rates to AET have been disappointing. Based
preliminary data and published reports supporting a role for cytokine and estrogen sigon preliminary data and published reports supporting a role for cytokine and estrogen
naling crosstalk, we sought to test the hypothesis that there is an interplay between
signaling crosstalk, we sought to test the hypothesis that there is an interplay between
IL6/LIF cytokine signaling in the tumor microenvironment and estrogen signaling.
IL6/LIF cytokine signaling in the tumor microenvironment and estrogen signaling.
We analyzed primary patient tumors and found that patients with tumors in which
We analyzed primary patient tumors and found that patients with tumors in which
the stroma expresses IL6/LIF cytokines had shorter PFI on AET, with a statistically signifthe stroma expresses IL6/LIF cytokines had shorter PFI on AET, with a statistically significant decrease in PFI specifically in ER-positive tumors. We then mechanistically linked
icant decrease in PFI specifically in ER-positive tumors. We then mechanistically linked
this stromal IL6/LIF expression with tumor ER signaling by demonstrating that IL6/LIF
this stromal IL6/LIF expression with tumor ER signaling by demonstrating that IL6/LIF
signaling both increases tumor cell ERα expression and induces ER reporter gene activasignaling both increases tumor cell ERα expression and induces ER reporter gene activation.
tion. Following this demonstration of an interplay between cytokine and estrogen signalFollowing this demonstration of an interplay between cytokine and estrogen signaling, we
ing, we demonstrated that blockade of both pathways with the JAK inhibitor ruxolitinib
demonstrated that blockade of both pathways with the JAK inhibitor ruxolitinib in comin combination with the aromatase inhibitor letrozole resulted in synergistic cell killing in
bination with the aromatase inhibitor letrozole resulted in synergistic cell killing in vitro.
vitro. Letrozole was selected due to its common clinical use currently and oral bioavailaLetrozole was selected due to its common clinical use currently and oral bioavailability for
bility for patients. Furthermore, we postulate that letrozole blocks estrogen synthesis to
patients. Furthermore, we postulate that letrozole blocks estrogen synthesis to decrease
decrease estrogen signaling and break the feed-forward loop between estrogen and
estrogen signaling and break the feed-forward loop between estrogen and IL6/LIF cytokine
IL6/LIF cytokine signaling in the ovarian cancer tumor microenvironment. Finally, we
signaling in the ovarian cancer tumor microenvironment. Finally, we performed mouse
performed mouse model studies revealing that combined therapy with AET and cytokine
model studies revealing that combined therapy with AET and cytokine blockade improves
blockade improves treatment response in vivo. These in vivo studies did not show statistreatment response in vivo. These in vivo studies did not show statistically significant
tically significant decreases with combination therapy as compared to single agent treatdecreases with combination therapy as compared to single agent treatments; potential
ments; potential explanations include the rapid tumor growth of the cell line utilized
explanations include the rapid tumor growth of the cell line utilized and/or the drug
and/or the drug treatment doses utilized.
treatment doses utilized.
A primary strength of this study is the inclusion of CA-MSC to investigate the impact
A primary strength of this study is the inclusion of CA-MSC to investigate the impact
of the tumor microenvironment on response to AET in ovarian cancer. Our findings are
of the tumor microenvironment on response to AET in ovarian cancer. Our findings
consistent with other work demonstrating that tumor-stroma interactions lead to producare consistent with other work demonstrating that tumor-stroma interactions lead to
tion of growth factors capable of activating ERs through a ligand-independent pathway
production of growth factors capable of activating ERs through a ligand-independent
resulting in tumor proliferation [16]. We also incorporated patient-derived CA-MSC in
pathway resulting in tumor proliferation [16]. We also incorporated patient-derived CAour animal models to recapitulate the tumor stroma. An additional strength of our work
MSC in our animal models to recapitulate the tumor stroma. An additional strength of our
work is the analysis of primary, patient-derived specimens that demonstrate a link between
stromal cytokine expression and response to AET.
This study also has several limitations that will serve to drive future directions. Larger
patient sample numbers will allow more robust conclusions; we are currently generating a

Cancers 2022, 14, 4675

10 of 11

tissue microarray of primary patient tumors to allow this analysis. Furthermore, antiestrogens with different mechanisms of action than the aromatase inhibitors studied herein may
also have unique effects on cytokine-estrogen crosstalk, and studies on selective estrogen
degraders (SERDs) would be beneficial. Continued in vivo preclinical studies are also
necessary to optimize both the optimal antiestrogen agent and dosing to achieve synergy
as compared to single agent treatment in animal models.
Additionally, our current study does not address the role of the immune component
of the tumor microenvironment in cytokine signaling and response to therapy. Prior work
has demonstrated that LIF and IL6 cytokines in ovarian cancer ascites promote the differentiation of monocytes into immunosuppressive tumor-associated macrophages [17,18].
These findings suggest that cytokine blockade such as that proposed herein would improve treatment responses. Additionally, other studies have revealed that ER signaling
functions to suppress immune function in tumors [19,20]. Thus, combination therapeutic
approaches incorporating AET would, if anything, be postulated to enhance antitumor
immune responses. Collectively, these links warrant further studies in immunocompetent
mouse model systems or humanized mouse models that would allow integration of both
patient-derived MSC and immune cells.
5. Conclusions
In conclusion, the findings reported herein demonstrate a link between IL6/LIF
cytokine signaling in the ovarian cancer tumor microenvironment and tumor cell estrogen
signaling. Dual blockade of both cytokine signaling and estrogen signaling has the potential
to block this crosstalk, improving antitumor responses. Additional preclinical studies will
allow refinement of this treatment approach and subsequent translation to clinical trials,
with the goal of improving ovarian cancer patient outcomes.
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